Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Garfield Samuels

Internal Medicine Virginia Beach, VA Medical Doctor

NPI 1083654669 CMS profile 94625

4452 Corporation Ln, Ste 300, Virginia Beach, VA 23462

Open in the dashboard

General payments

$10,010

568 records reported · program years 2019–2025

Research payments

$29,089

Paid to them · 11 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$113,612 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Garfield Samuels of Virginia Beach, VA is reported in the CMS Open Payments database as having received $10,010 across 568 general payments and $29,089 in research payments paid to them. Separately, studies naming them as principal investigator received $113,612 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $29 1
2023 General $413 11
2022 General $2,653 148
2021 General $2,930 166
2020 General $1,740 112
2020 Research $5,662 5
2019 General $2,245 130
2019 Research $23,427 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Garfield Samuels
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Garfield Samuels were reported at $29. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Garfield Samuels Internal Medicine median Middle half National median
2019 $2,245 $159 $48–$570 $163
2020 $1,740 $119 $33–$402 $114
2021 $2,930 $135 $37–$521 $132
2022 $2,653 $141 $42–$496 $149
2023 $413 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $29 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,810 90 payments
  2. GlaxoSmithKline, LLC. $756 41 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $678 54 payments
  4. Sanofi-Aventis U.S. LLC $646 34 payments
  5. Novo Nordisk Inc $642 45 payments
  6. Pfizer Inc. $566 36 payments
  7. Lilly USA, LLC $564 33 payments
  8. Amgen Inc. $525 15 payments
  9. Sunovion Pharmaceuticals Inc. $436 30 payments
  10. AbbVie, Inc. $383 23 payments
  11. Other $3,006 167 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,834 562 payments
  2. Education $176 6 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $966 50 payments
  2. XIFAXAN $678 54 payments
  3. TRELEGY ELLIPTA $600 30 payments
  4. BREZTRI $553 19 payments
  5. Ozempic $412 29 payments
  6. RYBELSUS $373 26 payments
  7. VRAYLAR $369 22 payments
  8. SYMBICORT $368 19 payments
  9. Otezla $349 11 payments
  10. Kerendia $339 14 payments
  11. Other $7,102 423 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Kowa Research Institute, Inc. $29,089 11 payments

Records

579 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record